Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RM-1929…click here to continue reading
Press Releases
Home > Press Releases > SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018
Pipeline
Pipeline
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
© Rakuten Medical Inc. 2022, All rights reserved.